lung adenocarcinoma
Conditions
Interventions
Control:None
Treatment:Patients to receive adjuvant therapy with gefitinib(250mg, once a day) or icotinib (125 mg, three times daily) for 24 months or to undergo observation until disease progression or intolerab
Sponsors
Weihai Municipal Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 78 Years
Inclusion criteria
Inclusion criteria: Patients with single primary lung cancer, a full set of tumor marker tests, blood biochemistry tests and related routine blood tests, enhanced CT of the chest, CT or ultrasound of the abdomen (liver, gallbladder, pancreas, spleen, kidneys, and adrenal glands), ultrasound of the cervical and supraclavicular lymph nodes, MR of the head or CT of the head, and whole-body bone imaging were all perfected to exclude metastasis before surgery; Complete surgical resection of the tumor with guaranteed negative margins (R0), the patient's surgical approach can be lobectomy, segmental resection, wedge resection of the lung, and regional lymph node sampling;Postoperative pathologically confirmed stage I lung adenocarcinoma (according to the 8th edition of the AJCC TNM staging system for lung cancer) with micropapillary or solid-type components;and had a confirmed EGFR mutation(exon 19 deletion or exon 21 L858R);Eligible patients were between 18 and 75 years of age; had an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1.
Exclusion criteria
Exclusion criteria: Patients with multiple high-risk lung nodules; prior treatment with antitumor agents or radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;safety; | — |
Countries
China
Contacts
Public ContactHuaijun Ji
Weihai Municipal Hospital
Outcome results
None listed